title: [Effects of phospholipid hepatoprotective agents in experimental Reye syndrome].
authors.forename: A S
authors.initials: AS
authors.lastname: Saratikov
authors.forename: A I
authors.initials: AI
authors.lastname: Vengerovskiĭ
authors.forename: I V
authors.initials: IV
authors.lastname: Sukhodolo
authors.forename: V S
authors.initials: VS
authors.lastname: Chuchalin
authors.forename: A G
authors.initials: AG
authors.lastname: Arbuzov
authors.forename: M B
authors.initials: MB
authors.lastname: Cherviakova
authors.forename: V N
authors.initials: VN
authors.lastname: Burkova
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D002338:Carotenoids / Q000627:therapeutic use*; D004338:Drug Combinations; D005229:Fatty Acids, Monounsaturated; D008099:Liver / Q000187:drug effects* / Q000473:pathology; D008297:Male; D010713:Phosphatidylcholines / Q000627:therapeutic use; D010743:Phospholipids / Q000627:therapeutic use*; D051381:Rats; D012202:Reye Syndrome / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000975:Antioxidants; D004338:Drug Combinations; D005229:Fatty Acids, Monounsaturated; D010713:Phosphatidylcholines; D010743:Phospholipids; C064845:eplir; C011246:essential 303 forte; D002338:Carotenoids; C009785:4-pentenoic acid